Course Summary
Fluphenazine is an antipsychotic that is used for the treatment of patients who have a psychotic disorder. It is used off-label to treat chorea associated with Huntington’s disease, chronic tic disorders, psychosis, and agitation associated with dementia. Fluphenazine is a piperazine phenothiazine. The phenothiazines are a class of medications that are used as antiemetics and to treat psychiatric disorders. Fluphenazine’s mechanism of action is not completely understood, but its antipsychotic effect is likely mediated through selective blockade of dopamine receptors in the brain. Fluphenazine may also affect peripheral alpha-adrenergic receptors, histamine receptors, and muscarinic receptors, but fluphenazine’s ability to block these receptors is considered limited.
Course Format
Homestudy
Course Syllabus
- Introduction
- Pharmacological Profile
- Labeled and Off-label Use
- Dosing and Available Forms
- US Boxed Warning, Contraindications, and Adverse Effects
- Warnings and Precautions
- Anticholinergic Effects
- Cardiovascular
- Central Nervous System
- Neuroleptic Malignant Syndrome
- Gastrointestinal
- Hematologic
- Ophthalmic
- Prolactin Levels
- Seizure Disorder
- Venous Thromboembolism
- Pregnancy and Breastfeeding
- Drug Interactions, Withdrawal/Discontinuation
- Overdose
- Case Study: Fluphenazine
- Summary
Author
Richard Daniels, PharmD, BCPS
Richard “Cole” Daniels earned his Doctor of Pharmacy(PharmD) from the Skaggs School of Pharmacy at the University of Montana in 2018. Throughout pharmacy school he completed a 3-year internship at Community Medical Center in Missoula, Montana in which he gained valuable experience in an acute care setting. Cole currently serves as a psychiatric clinical staff pharmacist at the Montana State Hospital. He has over 11 years of pharmacy experience having worked in several settings including retail, acute care, and inpatient psychiatric care. Cole has a diverse set of interests. However, acute care medicine, infectious disease, pain management, and asthma/COPD are a primary focus of his at the Montana State Hospital. He obtained board certification as a certified pharmacotherapy specialist in the Spring of 2022.
